BVX-M001: Phase II start

In October, BiondVax will begin a double-blind, Israeli Phase II trial to evaluate 500 µg adjuvanted Multimeric-001 injection vs. adjuvanted and non-adjuvanted placebo solution in 160 volunteers. ...